NSABP Members' Area
  Password Protected - Access
  Limited to NSABP Participating
  Institutions Only


NSABP Foundation, Inc.



General NSABP Information
  Financial Conflicts of
     Interest Policy
  Coalition Comment:
     Reconfiguration
  IOM Report Group Comment
  Contact the NSABP
  Pathology Section
  Future Meetings
  NSABP Newsletters
  Media Info on STAR
  Employment

Clinical Trials Information
  Clinical Trials Overview
  Protocol Chart
  Never Say Lost

Treatment Trials Information
  Protocol B-43
  Protocol B-47
  Protocol B-51

Prevention Trials Information
  Protocol P-1 - BCPT
  Protocol P-2 - STAR
  Protocol P-5
  BreastCancerPrevention.com

Scientific Publications

Related Web Sites



Medical Search Engines



To report problems, ask
questions or make comments,
please send e-mail to:
Webmaster@nsabp.pitt.edu

NSABP Clinical Trials Overview


Protocol B-30
A Three-Arm Randomized Trial To Compare Adjuvant Adriamycin And Cyclophosphamide Followed By Taxotere (AC6T); Adriamycin And Taxotere (AT); And Adriamycin, Taxotere, And Cyclophosphamide (ATC) In Breast Cancer Patients With Positive Axillary Lymph Nodes

Specific Aims
The primary aims of this phase III trial are to determine whether four cycles of post-operative Adriamycin (A: 50 mg/m2) and Taxotere (T: 75 mg/m2) and cyclophosphamide (C: 500 mg/m2) will more effectively prolong disease-free survival (DFS) and overall survival (S) of patients with node-positive breast cancer than will four cycles of AC (A: 60 mg/m2 and C: 600 mg/m2) followed by four cycles of Taxotere (100 mg/m2), and if four cycles of post-operative AT (A: 50 mg/m2 and T: 75 mg/m2) is at least as efficacious as the regimens containing cyclophosphamide. Secondary aims include comparing toxicities among the three regimens; comparing the quality of life (QOL) among breast cancer patients receiving one of the following treatments: ATC, AC→T, or AT; and examining differences in amenorrhea in premenopausal women in each treatment arm, and its relationship to symptoms, QOL, and DFS and S.